Dilated cardiomyopathy is a disease where the heart's main pumping chamber enlarges and weakens, reducing its ability to push blood forward. It affects about 1 in 2,500 people and can run in families or arise from viral infections, alcohol use, chemotherapy, or other causes. Standard treatment includes medications to reduce strain on the heart, and many people live years with stable disease.
What's actually going on in research
Trials are testing gene therapies for inherited forms, SGLT2 inhibitors that have shown heart protection in diabetes and heart failure, and devices that reshape the heart chamber to improve pumping. Researchers are also studying ways to identify people at risk for sudden cardiac arrest and testing new heart failure medications that might reverse some of the damage.
Gene therapy for inherited DCM
Several trials are testing gene therapies for cardiomyopathy caused by mutations in genes like TTN and LMNA. These therapies deliver corrected genetic instructions directly to heart muscle cells.
SGLT2 inhibitors
Drugs like empagliflozin and dapagliflozin, originally for diabetes, reduce heart failure hospitalizations and may help the heart remodel over time. They're now FDA-approved for heart failure and being studied specifically in dilated cardiomyopathy.
Cardiac contractility modulation
Devices that deliver electrical signals to strengthen heart muscle contractions are being tested in people who don't qualify for standard pacemakers. Early results suggest improved symptoms and quality of life.
What to know before you search
Eligibility typically depends on ejection fraction (how well the heart pumps), symptom severity, genetic testing results if relevant, and response to standard medications.
What types of trials are currently open
- Medication trials — Testing new heart failure drugs or repurposed medications like SGLT2 inhibitors to see if they improve heart function or reduce symptoms.
- Gene therapy trials — For people with inherited dilated cardiomyopathy, testing therapies that deliver corrected genes to heart muscle.
- Device trials — Testing pacemakers, defibrillators, or devices that reshape the heart to improve pumping efficiency.
- Natural history studies — Following people with dilated cardiomyopathy over time to understand how the disease progresses and what predicts outcomes.
- Biomarker studies — Using imaging, blood tests, or genetic testing to identify who's at highest risk for sudden death or rapid decline.
Recently added Dilated Cardiomyopathy trials
Take a daily pill to evaluate long-term effects on inherited heart disease
Danicamtiv is an investigational medication, which means it is still being studied and has not been approved. The purpose of this study is to learn how well danicamtiv works, how safe it is, how well people can take it when used in patients with genetic or familial dilated cardiomyopathy (DCM). There are currently no approved medicines made specifically to treat genetic or familial DCM.
Take a diabetes medicine being tested for pediatric heart failure
the study to investigate the efficacy of empagiflozin in pediatric heart failure
Find Dilated Cardiomyopathy trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.